Vitamin D-A prominent immunomodulator to prevent COVID-19 infectionReview Published on 2023-01-012023-07-10 Journal: International journal of rheumatic diseases [Category] COVID19(2023년), [키워드] doses immune system mechanism severe acute respiratory syndrome coronavirus 2 vitamin D. [DOI] 10.1111/1756-185X.14477 PMC 바로가기 [Article Type] Review
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study건강한 성인에서 이종 및 동종 불활성화 및 아데노바이러스 매개 COVID-19 백신 요법의 안전성 및 면역원성: 전향적 코호트 연구Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Adults adverse event adverse events Antibody Response AstraZeneca ChAdOx1 ChAdOx1-S circulating variants combinations CoronaVac country COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Efficacy Evidence evidence of followed by group groups healthy Heterologous heterologous adenoviral vector heterologous vaccine homologous IgA response immune response immune responses immunized immunogenicity inactivated Inactivated vaccine interferon gamma Mild neutralizing activities Neutralizing activity prospective cohort study reactogenicity Receptor-binding domain referred to regimen Safety Serious Adverse Event Serious Adverse Events supply shortage vaccination Vaccine variants variants of concern Viral viral vectored. wild-type [DOI] 10.1080/21645515.2022.2029111 PMC 바로가기 [Article Type] Article
COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach영국 웨일즈에서 50세 이상 성인의 COVID-19 백신 섭취 및 효과: 120만 인구 데이터 연결 코호트 접근법Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] 95%CI Adult affected Alpha approach BNT162b2 ChAdOx1 ChAdOx1 vaccine ChAdOx1 vaccines Characteristics Cohort collected data Coverage COVID-19 COVID-19 vaccine COVID-19 vaccines death Delta dose doses Effectiveness estimate first dose followed by Hospital admission immunization Infection linkage of BNT162b2 Older outcome outcomes PCR positive PCR positive SARS-CoV-2 infection post vaccination predominant SARS-CoV-2 SARS-COV-2 infection schedule second dose Seven strain vaccination vaccination. Vaccine variants Wales [DOI] 10.1080/21645515.2022.2031774 PMC 바로가기 [Article Type] Article
Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkersArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 바이오마커, 변종, 진단, [키워드] AstraZeneca Biomarker booster case-control study caused Chronic diseases Clinical severity conducted country COVID-19 COVID-19 confirmed patient COVID-19 patient COVID-19 vaccination COVID-19 vaccine CRP level Delta delta variant Delta wave dose doses effective Effectiveness Efficacy expressed females Health homologous homologous vaccination. hospital Hospitalization Hospitalized individual infected with SARS-CoV-2 Iraq Lower males molecular no significant difference no significant effect omicron Omicron variant pandemic Patient patients Pfizer Population Prevent recommendation recorded risk SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 variant severity significantly Symptom the disease the vaccine transmissibility of SARS-CoV-2 vaccination Vaccine variant variants of concern virus VOCs was done WBC [DOI] 10.1002/jmv.28098 PMC 바로가기
Protection against Omicron from Vaccination and Previous Infection in a Prison SystemArticle Published on 2022-11-102022-11-16 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Analysis B.1.1.529 B.1.617.2 booster collected Combination coronavirus Cox model dose doses effective Effectiveness estimate evaluate evaluated hazard ratio high-risk population Infection mRNA mRNA vaccination mRNA vaccine offered omicron Omicron variant prison protection ranged retrospective cohort risk of infection SARS-CoV-2 significantly more stratified System vaccination vaccine dose vaccine doses variant were used [DOI] 10.1056/NEJMoa2207082 PMC 바로가기
High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of OmicronArticle Published on 2022-11-052022-11-16 Journal: BMC Infectious Diseases [Category] SARS, 변종, [키워드] 95% CI Admission caused Cohort cohort analysis COVID-19 COVID-19 hospitalization COVID-19 vaccines dose doses Effectiveness elderly Elderly cohort evaluated Follow-up hazard ratio Heterologous homologous Hospitalization ICU ICU treatment Immunity individuals intensive care omicron outcome protection reduced remained restored SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 Omicron variant severe COVID-19 vaccination Vaccine waned Waning vaccine effectiveness. [DOI] 10.1186/s12879-022-07814-4 PMC 바로가기
Immunogenicity of Third-dose BNT162b2 mRNA Vaccine Following Two Doses of ChAdOx1 in Health Care Workers: A Prospective Longitudinal StudyArticle Published on 2022-11-012022-11-16 Journal: Annals of laboratory medicine [Category] SARS, 변종, [키워드] acute respiratory syndrome analyzed anti-S antibody BNT162b2 BNT162b2 mRNA ChAdOx1 collected Concentration coronavirus Coronavirus disease-19 COVID-19 delta variant demonstrated dose doses Effectiveness Efficacy eight healthcare worker help immunogenicity longitudinal NAbs Neutralizing neutralizing antibody occurred omicron outbreak pandemic predicted produced Prospective PROTECT reached regimen risk second dose study period the vaccine Three-dose vaccination. university hospital vaccination vaccination rate variant variants of concern Wuhan-Hu-1 [DOI] 10.3343/alm.2022.42.6.688 PMC 바로가기
Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosisArticle Published on 2022-11-012022-11-16 Journal: Journal of hepatology [Category] SARS, 변종, [키워드] 95% CI appear B.1.1.529 B.1.617.2 BNT BNT162b2 BNT162b2 mRNA booster booster dose chronic liver disease cirrhosis compensated Control control group COVD-19 COVID-19 COVID-19 in patient COVID-19 vaccines COVID-19-related death Critical dose doses General population greater hepatic decompensation hyporesponsiveness immune dysregulation liver magnitude moderate Moderate COVID-19 Moderna mRNA-1273 vaccine mRNA vaccine mRNA-1273 mRNA-1273. outcome overcome participant Patient Pfizer predominant receipt reduction in retrospective cohort study risk of infection Support symptomatic the vaccine Vaccine Vaccines variants veteran with COVID-19 [DOI] 10.1016/j.jhep.2022.07.036 PMC 바로가기
Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccinesArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] SARS, 변종, 진단, [키워드] 95% CI 95% confidence interval Ad26.COV2-S Administered Admission adverse event adverse events adverse events. age analyzed anti-SARS-CoV-2 vaccine BNT162b2 calculated Campylobacter jejuni ChAdOx1 collected CoronaVac COVID-19 diarrhea died dose doses epidemiological Guillain-barrè syndrome immunization inactivated incidence interquartile range Intravenous immunoglobulin male median Mild mRNA-1273 mRNA-based Patient performed plasma positive provided recipient reported risk SARS-CoV-2 Seven Surveillance survivor symptom onset syndrome tested treated vaccination Vaccine Vaccines variant [DOI] 10.1111/ene.15504 PMC 바로가기
SARS-Cov-2 infection in cancer patients, susceptibility, outcome and careArticle Published on 2022-11-012022-11-15 Journal: The American journal of the medical sciences [Category] COVID19(2023년), SARS, 진단, [키워드] anti-cancer treatment antibody benefit Cancer Cancer patients cancers Care coronavirus COVID-19 COVID-19 pandemic doses Factor generate healthy hematologic impacted implication increased risk individuals Infection knowledge observation outcome Pandemics Patient patients Perception problem response to vaccination risk SARS-CoV-2 SARS-COV-2 infection shown susceptibility Vaccines. virus [DOI] 10.1016/j.amjms.2022.05.017 PMC 바로가기